Based on encouraging preclinical data showing that the deleterious pro-oncogenic arm of the TGF-β biological response program can be effectively blockaded for therapeutic benefit, TGF-β antagonists are now in early phase clinical trials in oncology in several tumor types [6], including breast cancer (http://clinicaltrials.gov Trial NCT01401062). The gene discussed is TGFB1; the disease is neoplasm.